Rodman & Renshaw taps John Chambers to lead new biotech industry group

By Laura Lutz

Des Moines, Nov. 2 - Rodman & Renshaw announced the formation of a new life-sciences industry division, Acumen BioFin, and appointed John Chambers as president of the new group.

Acumen BioFin will specialize in banking services for the biotechnology, pharmaceuticals and medical devices sectors.

Chambers has held senior positions in biotechnology investment banking at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney.

"Acumen BioFin's research, sales & trading and investment banking professionals combine a deep expertise in the life-sciences industry with extensive Wall Street experience to meet successfully the ever changing and evolving needs of our public and private life sciences client base," Chambers said in the release.

Rodman & Renshaw is an investment and merchant bank with headquarters in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.